Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of isorhamnetin in preparation of drugs for treatment of pulmonary hypertension

A pulmonary arterial hypertension and isorhamnetin technology is applied in the direction of drug combinations, pharmaceutical formulations, and medical preparations containing active ingredients, etc., to reduce the remodeling of small and medium pulmonary arteries, reduce right heart hypertrophy index, reduce mean pulmonary arterial pressure and right Effects on Ventricular Systolic Pressure

Pending Publication Date: 2020-01-07
NINGXIA MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether isorhamnetin has a protective effect on pulmonary hypertension has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of isorhamnetin in preparation of drugs for treatment of pulmonary hypertension
  • Use of isorhamnetin in preparation of drugs for treatment of pulmonary hypertension
  • Use of isorhamnetin in preparation of drugs for treatment of pulmonary hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1: The use of isorhamnetin as a drug for the treatment of pulmonary arterial hypertension, the structural formula of isorhamnetin is shown in formula (1):

[0041]

[0042] Wherein, the single application dose of isorhamnetin is limited to the dose that does not cause central nervous system depression, the single application dose of isorhamnetin is 50 mg / kg for rats, and the dosage form of the drug is a solution dosage form.

Embodiment 2

[0043] Example 2: The use of isorhamnetin as a drug for the treatment of pulmonary arterial hypertension, the structural formula of isorhamnetin is shown in formula (1):

[0044]

[0045] Wherein, the single application dose of isorhamnetin is limited to the dose that does not cause central nervous system depression, the single application dose of isorhamnetin is 100 mg / kg for rats, and the dosage form of the drug is a solution dosage form.

Embodiment 3

[0047] Isorhamnetin is used as a drug for the treatment of pulmonary arterial hypertension, and the structural formula of isorhamnetin is as shown in formula (1):

[0048]

[0049]Wherein, the single application dose of isorhamnetin is limited to the dose that does not cause central nervous system inhibition, the single application dose of isorhamnetin is 150 mg / kg for rats, and the dosage form of the drug is a solution dosage form.

[0050] The following animal experiment has further illustrated the effect of above-mentioned embodiment 1 to 3:

[0051] 1. Experimental materials

[0052] 1.1 Animal handling

[0053] Adult male SD rats, 230-250g, were purchased from the Experimental Animal Center of Ningxia Medical University, animal production license number: NCXK (Ning) 2016-0005. Feeding conditions include standard feed, tap water, room temperature maintained at (24±2)°C, humidity 50-60%, and daily light and dark times of 12 hours each. Before the experiment, the anima...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of isorhamnetin in preparation of drugs for treatment of pulmonary hypertension. The isorhamnetin is applicated at a dose of 50-150mg / kg, hemodynamic parameters and echocardiographic parameters of pulmonary hypertension model rats can be significantly improved, and reconstruction of a right ventricle and pulmonary small arteries are reduced.

Description

[0001] a technical field [0002] The invention belongs to the field of cardiovascular diseases. Specifically, the invention provides the use of isorhamnetin in the preparation of medicines for treating pulmonary hypertension. [0003] Two background technology [0004] Pulmonary arterial hypertension (PAH) is a group of diseases or clinical syndromes characterized by elevated pulmonary artery pressure and pulmonary vascular circulatory resistance caused by different etiologies. Volume overload increased until death and was considered a "pseudo-malignancy". Pulmonary artery occlusion caused by proliferation of vascular smooth muscle cells (VSMC) and pulmonary vascular remodeling are considered to be the main features of the pathogenesis and pathological changes of PAH. Due to the increase of pulmonary vascular resistance and the increase of right ventricular afterload, right ventricular remodeling is caused, which eventually leads to right ventricular failure. With the in-dep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P9/12A61P11/00
CPCA61K31/352A61P9/12A61P11/00
Inventor 周茹常智周玮郝银菊张鹏徐清斌裴延敏王佳玲余洋
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com